Docetaxel has an established role in the treatment of metastatic castrate-resistant prostate cancer.
A number of recent treatments have been shown to improve the survival outcomes for this group of patients and many with improved toxicity profiles, bringing the role of docetaxel into question. We discuss the results and implications of the CHAARTED study that demonstrated a significant improvement in overall survival with docetaxel in metastatic hormone-sensitive prostate cancer.
Voskoboynik M, Staffurth J, Malik Z, Sweeney C, Chowdhury S. Are you the author?
Department of Medical Oncology, Guy's Hospital, Great Maze Pond, London, UK.
Reference: Expert Rev Anticancer Ther. 2014 Nov;14(11):1253-6.